Diana Graus Porta

3.4k total citations
21 papers, 1.9k citations indexed

About

Diana Graus Porta is a scholar working on Molecular Biology, Cancer Research and Surgery. According to data from OpenAlex, Diana Graus Porta has authored 21 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 6 papers in Cancer Research and 2 papers in Surgery. Recurrent topics in Diana Graus Porta's work include Fibroblast Growth Factor Research (18 papers), Kruppel-like factors research (8 papers) and Cancer, Hypoxia, and Metabolism (6 papers). Diana Graus Porta is often cited by papers focused on Fibroblast Growth Factor Research (18 papers), Kruppel-like factors research (8 papers) and Cancer, Hypoxia, and Metabolism (6 papers). Diana Graus Porta collaborates with scholars based in Switzerland, United States and France. Diana Graus Porta's co-authors include Pascal Furet, Josef Brueggen, Francesco Hofmann, Vito Guagnano, Carlos Garcı́a-Echeverrı́a, Christelle Stamm, Dean B. Evans, Mark Pearson, Thomas Meyer and Juergen Mestan and has published in prestigious journals such as The Journal of Cell Biology, PLoS ONE and Hepatology.

In The Last Decade

Diana Graus Porta

21 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Diana Graus Porta Switzerland	14	1.3k	419	323	245	241	21	1.9k
Claudia Miranda Italy	22	776 0.6×	410 1.0×	207 0.6×	301 1.2×	327 1.4×	33	1.5k
Alessandra Pattarozzi Italy	31	1.0k 0.8×	815 1.9×	329 1.0×	306 1.2×	211 0.9×	51	2.1k
Domenico Maglione Italy	12	1.6k 1.2×	508 1.2×	424 1.3×	109 0.4×	188 0.8×	14	2.2k
Nathalie Baeza France	17	1.2k 0.9×	431 1.0×	561 1.7×	131 0.5×	226 0.9×	28	2.2k
Tetsu Yamane Japan	22	710 0.6×	584 1.4×	288 0.9×	127 0.5×	282 1.2×	44	1.5k
Hany Kayed Germany	23	923 0.7×	640 1.5×	263 0.8×	63 0.3×	138 0.6×	45	1.5k
Elena Arighi Italy	17	1.2k 0.9×	682 1.6×	180 0.6×	515 2.1×	130 0.5×	19	1.9k
Armelle Logié United Kingdom	19	962 0.7×	442 1.1×	433 1.3×	206 0.8×	202 0.8×	33	1.6k
Fabienne Baffert Switzerland	13	968 0.8×	434 1.0×	341 1.1×	62 0.3×	223 0.9×	19	1.5k
Carla A. Borgoño Canada	24	725 0.6×	785 1.9×	413 1.3×	95 0.4×	121 0.5×	31	2.3k

Countries citing papers authored by Diana Graus Porta

Since Specialization

Citations

This map shows the geographic impact of Diana Graus Porta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Diana Graus Porta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Diana Graus Porta more than expected).

Fields of papers citing papers by Diana Graus Porta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Diana Graus Porta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Diana Graus Porta. The network helps show where Diana Graus Porta may publish in the future.

Co-authorship network of co-authors of Diana Graus Porta

This figure shows the co-authorship network connecting the top 25 collaborators of Diana Graus Porta. A scholar is included among the top collaborators of Diana Graus Porta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Diana Graus Porta. Diana Graus Porta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wilbaux, Mélanie, Shu Yang, Astrid Jullion, et al.. (2022). Integration of Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy into Model‐Informed Dose Selection in Oncology First‐in‐Human Study: A Case of Roblitinib (FGF401). Clinical Pharmacology & Therapeutics. 112(6). 1329–1339. 6 indexed citations

Huynh, Hung, Thi Bich Uyen Le, Huai-Xiang Hao, et al.. (2020). FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma. Experimental & Molecular Medicine. 52(11). 1857–1868. 19 indexed citations

Huynh, Hung, Kah Yong Goh, Richard Ong, et al.. (2018). Infigratinib Mediates Vascular Normalization, Impairs Metastasis, and Improves Chemotherapy in Hepatocellular Carcinoma. Hepatology. 69(3). 943–958. 53 indexed citations

Weiss, Andreas, Diana Graus Porta, Christelle Stamm, et al.. (2017). Abstract 2103: NVP-FGF401: Cellular and in vivo profile of a novel highly potent and selective FGFR4 inhibitor for the treatment of FGF19/FGFR4/KLB+ tumors. Cancer Research. 77(13_Supplement). 2103–2103. 5 indexed citations

Goyal, Lipika, Supriya K. Saha, Leah Y. Liu, et al.. (2017). Abstract 4114: Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in FGFR2 fusion-positive cholangiocarcinoma patients. Cancer Research. 77(13_Supplement). 4114–4114. 4 indexed citations

Chan, Stephen L., Chia‐Jui Yen, Martin Schüler, et al.. (2017). Abstract CT106: Ph I/II study of FGF401 in adult pts with HCC or solid tumors characterized by FGFR4/KLB expression. Cancer Research. 77(13_Supplement). CT106–CT106. 22 indexed citations

Porta, Diana Graus, Andreas Weiss, Robin A. Fairhurst, et al.. (2017). Abstract 2098: NVP-FGF401, a first-in-class highly selective and potent FGFR4 inhibitor for the treatment of HCC. Cancer Research. 77(13_Supplement). 2098–2098. 8 indexed citations

Sequist, Lecia V., Andréa Varga, Josep Tabernero, et al.. (2014). Abstract CT326: Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors. Cancer Research. 74(19_Supplement). CT326–CT326. 68 indexed citations

Sequist, Lecia V., Andréa Varga, Josep Tabernero, et al.. (2014). Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors. Kölner Universitäts PublikationsServer (Universität zu Köln). 29 indexed citations

10.

André, Fabrice, Thomas Bachelot, Mario Campone, et al.. (2013). Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer. Clinical Cancer Research. 19(13). 3693–3702. 251 indexed citations

11.

Wöhrle, Simon, Andreas Weiss, Moriko Ito, et al.. (2013). Fibroblast Growth Factor Receptors as Novel Therapeutic Targets in SNF5-Deleted Malignant Rhabdoid Tumors. PLoS ONE. 8(10). e77652–e77652. 39 indexed citations

12.

Kim, Sungeun, Anna Dubrovska, Richard J. Salamone, et al.. (2013). FGFR2 Promotes Breast Tumorigenicity through Maintenance of Breast Tumor-Initiating Cells. PLoS ONE. 8(1). e51671–e51671. 48 indexed citations

13.

Konecny, Gottfried E., Teodora Kolarova, Neil A. O’Brien, et al.. (2013). Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer Cells. Molecular Cancer Therapeutics. 12(5). 632–642. 68 indexed citations

14.

Finn, Richard S., Danyun Zhao, Lee Anderson, et al.. (2012). Abstract 3858: Gains in FGF19 are predictive of response to the fibroblast growth factor receptor (FGFR) small molecule tyrosine kinase inhibitor BGJ 398 in vitro. Cancer Research. 72(8_Supplement). 3858–3858. 13 indexed citations

15.

Wöhrle, Simon, Olivier Bonny, Nancy E. Hynes, et al.. (2012). Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. Journal of Bone and Mineral Research. 28(4). 899–911. 125 indexed citations

16.

Shi, Michael, Ronald Linnartz, Richard Versace, et al.. (2011). Abstract 3575: Dovitinib (TKI258), a dual inhibitor of FGFR and VEGFR, induces tumor growth suppression in xenograft models of human bladder cancer. Cancer Research. 71(8_Supplement). 3575–3575. 2 indexed citations

17.

Guagnano, Vito, Diana Graus Porta, Vincent Bordas, et al.. (2011). Abstract B246: NVP-BGJ398: A potent and selective inhibitor of the fibroblast growth factor receptor family.. Molecular Cancer Therapeutics. 10(11_Supplement). B246–B246. 1 indexed citations

18.

Guagnano, Vito, Pascal Furet, Carsten Spanka, et al.. (2011). Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase. Journal of Medicinal Chemistry. 54(20). 7066–7083. 378 indexed citations

19.

Garcı́a-Echeverrı́a, Carlos, Mark Pearson, Andreas Marti, et al.. (2004). In vivo antitumor activity of NVP-AEW541—A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell. 5(3). 231–239. 447 indexed citations

20.

Feltri, M. Laura, Diana Graus Porta, Stefano C. Previtali, et al.. (2002). Conditional disruption of β1 integrin in Schwann cells impedes interactions with axons. The Journal of Cell Biology. 156(1). 199–210. 269 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact